Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels

Rituximab (RTX) and cyclophosphamide (CYC) based treatments are both recommended as first-line therapies in idiopathic membranous nephropathy (IMN) by KDIGO 2021 guideline. However, the efficacy of RTX vs. CYC-based treatments in IMN is still controversial. We performed this systemic review and meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Cheng, Wang, Jian, Pan, Jinyan, Liang, Congdie, Zhou, Chenchen, Wu, Jun, Song, Shuwei, Cui, Linlin, Zhang, Liming, Liu, Yawei, Dai, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517553/
https://www.ncbi.nlm.nih.gov/pubmed/37740193
http://dx.doi.org/10.1186/s12882-023-03307-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517553/
https://www.ncbi.nlm.nih.gov/pubmed/37740193
http://dx.doi.org/10.1186/s12882-023-03307-x

Ejemplares similares